Bruker Corporation Unveils Groundbreaking Innovations in Mass Spectrometry for Drug Monitoring and Environmental Analysis at ASMS 2025

Reuters
06-03
Bruker Corporation Unveils Groundbreaking Innovations in Mass Spectrometry for Drug Monitoring and Environmental Analysis at ASMS 2025

Bruker Corporation has announced significant advancements in mass spectrometry technology at the 73rd American Society for Mass Spectrometry (ASMS) Conference. The company unveiled the timsMetabo™ platform, which offers high-sensitivity analysis for small molecules, specifically targeting PFAS and environmental contaminants. Additionally, Bruker introduced the integration of RECIPE's ClinMass® and ClinDART® assay kits with its EVOQ® DART-TQ⁺ system, aimed at improving therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis. These innovations are expected to enhance laboratory productivity by enabling high-throughput, chromatography-free workflows. Bruker plans to further develop solutions for forensic toxicology and emerging contaminants, underlining its commitment to addressing real-world analytical challenges.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603080303) on June 03, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10